2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - 260-262
Clinical issues with T cell engagers (scheduling, out-patient delivery, CRS prophylaxis, tumor flare, maintenance). One abstarct on bone modifying therapy in myeloma that didn't fit elsewhere.
Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

967 Incidence, clinical features, and outcomes of tumor flare after bispecific antibody therapy for relapsed/refractory multiple myeloma: A US myeloma immunotherapy consortium study

Andrew Jay Portuguese, MD, Guizhen Chen2, Manoj Rai, MD3, Ariel Grajales-Cruz, MD4, Omar Alexis Castaneda Puglianini, MD5, Doris K. Hansen, MD6, Rachid Baz, MD7, Jack Khouri, MD8, Mikhaila Rice, PharmD9, Shahzad Raza, MD10, Faiz Anwer, MD11, Nilesh Kalariya, APRN, PhD12, Mackenzie Maberry, MD13, Oren Pasvolsky, MD14, Danai Dima, MD15, Christy Khouderchah, PharmD, BCOP16, Prashant Kapoor, MD17, Saurabh Chhabra, MD, MBBS18, Sikander Ailawadhi, MD19, Nadine Abdallah I, MD20, Masooma Shifa Rana, MBBS21, Surbhi Sidana, MD22, Lekha Mikkilineni, MD, MA23, Samer Al Hadidi, MD24, Larry D Anderson Jr, MD, PhD25, James A Davis, PharmD, BCOP26, Anthony Dominick27, Timothy O'Brien, MD28, Francesca Cottini, MD29, Ashley Rosko, MD30, Darren Pan, MD31, Christopher J. Ferreri, MD32, Binoy Yohannan, MD33, Chenyu Lin, MD34, Noa Biran, MD35, Karen Sweiss, PharmD36, Megan M Herr, PhD37, Anita Nguyen38, Margaret Minett, N/A39, Nisha Joseph, MD40, Rebecca Silbermann, MD41, Rahul Banerjee, MD42, Sarvari V. Yellapragada, MD43, Susan Y. Wu, MD44
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 University of Washington, Seattle, Washington, United States
3 Oregon Health & Science University, Portland, Oregon, United States
4 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States
11 Cleveland Clinic, Cleveland, Ohio, United States
12 MD Anderson Cancer Center, Houston, Texas, United States
13 MD Anderson Cancer Center, Houston, Texas, United States
14 MD Anderson Cancer Center, Houston, Texas, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States
16 Fred Hutchinson Cancer Center, Seattle, Washington, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Phoenix, Arizona, United States
19 Mayo Clinic, Jacksonville, Florida, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Stanford University, Stanford, California, United States
22 Stanford University, Stanford, California, United States
23 Stanford University, Stanford, California, United States
24 UT Southwestern Medical Center, Dallas, Texas, United States
25 UT Southwestern Medical Center, Dallas, Texas, United States
26 Medical University of South Carolina, Charleston, South Carolina, United States
27 Medical University of South Carolina, Charleston, South Carolina, United States
28 UH Seidman Cancer Center, Cleveland, Ohio, United States
29 The Ohio State University, Columbus, Ohio, United States
30 The Ohio State University, Columbus, Ohio, United States
31 University of California San Francisco, San Francisco, California, United States
32 Levine Cancer Institute, Charlotte, North Carolina, United States
33 University of Minnesota, Minneapolis, Minnesota, United States
34 Duke University, Durham, North Carolina, United States
35 Hackensack Meridian Health, Hackensack, New Jersey, United States
36 University of Illinois, Chicago, Illinois, United States
37 Roswell Park, Buffalo, New York, United States
38 Washington University, St. Louis, Missouri, United States
39 Washington University, St. Louis, Missouri, United States
40 Winship Cancer Institute, Atlanta, Georgia, United States
41 Oregon Health & Science University, Portland, Oregon, United States
42 Fred Hutchinson Cancer Center, Seattle, Washington, United States
43 MD Anderson Cancer Center, Houston, Texas, United States
44 MD Anderson Cancer Center, Houston, Texas, United States

Background: While bispecific antibody (BsAb) therapies induce rapid responses in relapsed/refractory multiple myeloma (RRMM), tumor flare (TF) after BsAb therapy has been described and may be analogous to pseudoprogression following checkpoint inhibitors. We defined TF as antecedent signs or symptoms suggestive of true progression followed by subsequent clinical response. Because TF can be difficult to distinguish from true early progression, its recognition may prevent premature discontinuation of effective therapy. To date, TF following BsAb therapy in RRMM has only been analyzed in small case series.

Methods: We performed a 17-site US Myeloma Immunotherapy Consortium retrospective cohort study of patients with RRMM treated with commercial BsAbs. We included only the index commercial BsAb course and excluded bridging BsAb courses and courses with missing TF ascertainment. TF was defined as any of the following before a confirmed response: (1) acute increase in size of a known lesion with/without new symptoms or (2) unexplained increase in bone pain at a known site of disease. Baseline characteristics, best response, CRS, ICANS, and Kaplan-Meier PFS and OS were analyzed descriptively. Logistic and Cox models evaluated TF associations with response and survival, adjusting for age, ECOG performance status, sex, prior lines, HRCA, and true EMD; univariable logistic models assessed clinical correlates of documented TF, including CRS/ICANS and 30-day infections. Free-text descriptions were summarized using non-mutually exclusive clinical themes.

Results: Among 1,484 BsAb courses in 1,368 unique patients, median age was 69 years (range, 30-95); products were teclistamab (n=812; 54.7%), talquetamab (n=468; 31.5%), elranatamab (n=186; 12.5%), and linvoseltamab (n=18; 1.2%). TF was documented in 25 cases (1.7%; 95% exact CI, 1.1%-2.5%) and did not differ by product (Fisher p=0.969) or target class (BCMA-directed BsAbs 18/1016 [1.8%] vs talquetamab 7/468 [1.5%]; chi-squared p=0.701). Baseline disease activity markers were similar by TF status, including hemoglobin, LDH, albumin, ferritin, and CRP.

Responses were comparable by TF status: ORR was 68.0% with TF versus 67.4% without TF (Fisher p=1.00), VGPR or better was 48.0% versus 54.5% (p=0.689), and CR/sCR was 32.0% versus 34.2% (p=1.00). CRS was numerically more frequent with TF (68.0% vs 49.3%; p=0.064), ICANS was similar (20.0% vs 15.5%; p=0.575), and tocilizumab treatment was more common with TF (68.0% vs 34.6%; p<0.001). Infections within 30 days were similar with versus without TF (24.0% vs 22.4%; p=0.811), including severe infections (8.0% vs 7.1%; p=0.695). Among admitted patients, median hospital length of stay was 10 versus 9 days (IQR, 8-15 vs 7-11; p=0.017). TF was not associated with inferior adjusted response or survival, including ORR (adjusted OR 1.22; 95% CI, 0.48-3.07), PFS (adjusted HR 1.07; 95% CI, 0.65-1.76), or OS (adjusted HR 1.01; 95% CI, 0.57-1.79). In univariable clinical-correlates models, true EMD was associated with higher odds of documented TF (OR 2.84; 95% CI, 1.28-6.33; p=0.01).

Common TF manifestations included pain flare at a known lesion/plasmacytoma (48.0%), imaging-only worsening (36.0%), extramedullary/visceral or soft tissue flare (32.0%), lesion enlargement or new/enlarging mass (32.0%), laboratory or organ dysfunction (20.0%), and neurologic/CNS symptoms (16.0%). Timing was variably documented but generally occurred during step-up dosing or within the first 1-3 months. Additional analyses will be presented at the meeting.

Conclusions: In this multicenter real-world analysis, TF after commercial BsAb therapy was documented in 1.7% of treatment courses and was not associated with inferior response, PFS, or OS. However, this incidence is likely an underestimate given the retrospective design, lack of a standardized TF definition, and evolving clinical recognition of this entity. TF was associated with greater tocilizumab treatment use and longer hospitalization but not higher 30-day infection rates. Despite clinical heterogeneity, early pain flare or transient lesion enlargement followed by subsequent response were consistent clinical themes. True EMD may identify patients more likely to have documented TF, although the small number of TF events limits inference. These findings support the importance of recognizing TF to avoid premature discontinuation of effective BsAb therapy and support standardization of TF definition and management.

Andrew Jay Portuguese, MD: Pfizer - Research Funding; Regeneron - Research Funding; Karyopharm - Consultancy (Includes expert testimony)